Skip to content
Screener

SG&A at other companies

Abbott logo
AbbottABT
$4.03B+30.2%
Haemonetics logo
HaemoneticsHAE
$118.94M+7.4%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$152.2M+5.5%
Medtronic logo
MedtronicMDT
$3.06B+12.4%
ITG
Integer HoldingsITGR
$58.71M+14.8%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$118.21M+10.0%

Segments

By segment

See full
Cardiopulmonary$66.47M+18.7%
Neuromodulation$56.57M+10.7%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales116,917113,536235,426214,137
Gross profit273,670238,988517,419455,242
Operating expenses:
Selling, general, and administrative158,128137,780301,696266,926
Research and development53,66247,185112,35785,064
Other operating expense12,396(160)12,411452
Operating income49,48454,18390,955102,800
SNIA environmental liability expense(1,677)(362,070)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's SG&A?
LivaNova (LIVN) reported SG&A of $158.13M in Q2 2026.
How has LivaNova's SG&A changed year-over-year?
LivaNova's SG&A increased by 14.8% year-over-year, from $137.78M to $158.13M.
What is the long-term trend for LivaNova's SG&A?
Over 4 years (2021 to 2025), LivaNova's SG&A has grown at a 3.8% compound annual growth rate (CAGR), from $471.9M to $548.81M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about LivaNova's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude